Seres Therapeutics Inc [NASDAQ: MCRB] surged by $0.18 during the normal trading session on while it closed the day at $0.91.
Seres Therapeutics Inc stock has also gained 18.95% of its value over the past 7 days. However, MCRB stock has inclined by 7.59% in the 3 months of the year. Over the past six months meanwhile, it has lost -25.89% and gained 9.69% year-on date.
The market cap for MCRB stock reached $155.63 million, with 170.20 million shares outstanding and 124.81 million shares in the current float. Compared to the average trading volume of 2.68M shares, MCRB reached a trading volume of 11374773 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seres Therapeutics Inc [MCRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $3.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 2.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Seres Therapeutics Inc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 24, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on June 26, 2023, representing the official price target for Seres Therapeutics Inc stock. Previously, the target price had yet another raise to $7, while JP Morgan analysts kept a Neutral rating on MCRB stock. On July 23, 2021, analysts decreased their price target for MCRB shares from 24 to 7.
The Average True Range (ATR) for Seres Therapeutics Inc is set at 0.08, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 2593.81. The Price to Book ratio for the last quarter was 6.49, with the Price to Cash per share for the same quarter was set at 0.39.
MCRB stock trade performance evaluation
Seres Therapeutics Inc [MCRB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.95. With this latest performance, MCRB shares gained by 5.99% in over the last four-week period, additionally sinking by -25.89% over the last 6 months – not to mention a drop of -25.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 56.98, with the RSI for the last a single of trading hit 61.13, and the three-weeks RSI is set at 54.85 for Seres Therapeutics Inc [MCRB]. The present Moving Average for the last 50 days of trading for this stock 0.8209, while it was recorded at 0.7850 for the last single week of trading, and 0.8859 for the last 200 days.
Seres Therapeutics Inc [MCRB]: An insightful look at the core fundamentals
Seres Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.12 and a Current Ratio set at 1.12.
Seres Therapeutics Inc [MCRB]: Institutional Ownership
There are presently around $37.19%, or 42.84%% of MCRB stock, in the hands of institutional investors. The top three institutional holders of MCRB stocks are: FLAGSHIP PIONEERING INC. with ownership of 23.12 million shares, which is approximately 15.8226%. FMR LLC, holding 22.72 million shares of the stock with an approximate value of $$16.44 million in MCRB stocks shares; and FMR LLC, currently with $$4.55 million in MCRB stock with ownership which is approximately 4.3023%.
